Third Harmonic Bio
highly selective oral wild type kit inhibitor | Third Harmonic Bio
Company
Deck Type
IPO
Sector
Industry
Deck date
September 2022
Slide
7 of 24
Similar slides by Third Harmonic Bio
See diffirences between slides (animation)
Investor Presentation
October 2022
highly selective oral wild type kit inhibitor on | Third Harmonic Bio
Related slides by other companies
Ocuphire Pharma
Results
March 2022
addressing unmet needs in large markets | Ocuphire Pharma
Arbutus Biopharma
Investor Presentation
October 2023
oral inhibitor for immune reactivation | Arbutus Biopharma
BenevolentAI
Investor Presentation
October 2022
ben oral peripherally restricted inhibitor under development as a in class treatment for refractory ulcerative colitis an opportunity to differentiate on safety and a precision medicine approaches safety | BenevolentAI
DICE Therapeutics
Investor Presentation
March 2023
opportunity for oral inhibitor target indication validation via clinical commercial success of a dice | DICE Therapeutics
Other recent decks by Third Harmonic Bio
See all presentations (2 decks)
Investor Presentation
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io